Elanco Animal Health Incorporated (ELAN)

Market Cap	6.91B
Revenue (ttm)	4.43B
Net Income (ttm)	373.00M
Shares Out	496.65M
EPS (ttm)	0.75
PE Ratio	18.55
Forward PE	17.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,167,713
Open	13.99
Previous Close	13.90
Day's Range	13.61 - 14.02
52-Week Range	8.02 - 18.80
Beta	1.68
Analysts	Buy
Price Target	15.17 (+9.06%)
Earnings Date	May 7, 2025

About ELAN

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 20, 2018
• Employees: 9,450
• Stock Exchange: NYSE
• Ticker Symbol: ELAN
• Website: https://www.elanco.com

Analyst Forecast

According to 6 analysts, the average rating for ELAN stock is "Buy." The 12-month stock price forecast is $15.17, which is an increase of 9.06% from the latest price.

Price Target

$15.17

(9.06% upside)

Analyst Consensus: Buy